UBS Upgrades Teva Pharma (TEVA) to Neutral, 'the long value inflection timeline limits our enthusiasm'
Tweet Send to a Friend
(Updated - July 6, 2023 4:51 AM EDT)
UBS analyst Ashwani Verma upgraded Teva Pharma (NYSE: TEVA) from Sell ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst Ashwani Verma upgraded Teva Pharma (NYSE: TEVA) from Sell ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
